Moebius Medical

Executive Summary

Moebius Medical is an Israeli clinical-stage biotechnology company developing innovative intra-articular therapies for osteoarthritis using its proprietary large-empty multilamellar liposome (LEML) technology. Its lead candidate, MM-II, is a non-opioid, non-steroid injectable that provides durable pain relief and cartilage protection for knee osteoarthritis. The company is currently advancing MM-II through a global Phase 3 clinical trial in partnership with Sun Pharma, positioning it for potential market entry. With a strong mechanistic rationale and an experienced management team, Moebius Medical represents a compelling opportunity in the osteoarthritis treatment landscape.

Upcoming Catalysts (preview)

• Q4 2026Phase 3 Top-Line Data Readout for MM-II70% success
• TBDRegulatory Submission (NDA/MAA) for MM-II60% success